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Abstract
Aims/hypothesis: Insulin therapy is effective predominantly when dosage is frequently adjusted. However, a
controversy surrounds the pertinent clinical parameters required to make effective and safe frequent dosage
adjustments. We hypothesize that glucose readings are sufficient to adjust insulin dosage provided that dosage
is adjusted every 1–4 weeks.
Methods: To test the hypothesis, we generated several algorithms implemented in software to process glucose
readings and recommend insulin dosage adjustments. A post hoc analysis was made on 630 log sheets (2,520
insulin dosage adjustments) from 26 older adults with suboptimally controlled type 2 diabetes. The subjects were
followed for a year and treated with intensive insulin therapy that was titrated every 1–4 weeks by a trained study
team. More than 88% of subjects attained the treatment goal (hemoglobin A1c <7%) without excessive hypo-
glycemia. Glucose readings from each log sheet were used as an input to the software, and its recommendations
for insulin dosage adjustments were compared to the original ones made by the study team. While the study team
could have been exposed to multiple clinical parameters, the software relied solely on glucose readings.
Results: The software recommendations for dosage adjustments were clinically equivalent to the original study
team’s recommendations in more than 95% of the cases, unrelated to patients’ insulin sensitivity. The remaining
4.4% (n¼ 111) were thoroughly examined, yet we did not find any recommendations suggested by the software
to be unsafe or unreasonable.
Conclusions/Interpretation: Glucose readings are sufficient to effectively adjust insulin dosage provided that
adjustments are made every 1–4 weeks. Therefore, dedicated software can help adjusting insulin dosage be-
tween clinic visits.
Introduction
Insulin is the only antidiabetes agent lacking a thera-peutic window. In other words, most insulin-treated
patients can achieve satisfactory glycemic control provided
that appropriate formulations and adequate dosage are pre-
scribed. Yet, almost two-thirds of insulin-treated diabetes
patients in the United States fail to reach the therapy goal
(hemoglobin A1c [A1C] <7%),1,2 although compliance to an-
tidiabetes medications is generally considered adequate in
about three-fourths of the cases.3,4 Most insulin users have
type 2 diabetes; some use partial insulin therapy (premixed,
biphasic, or long-acting insulin), and some use intensive in-
sulin therapy (basal/bolus). Only clinical trials that reinforce
a policy of insulin dosage adjustments every 1–4 weeks
(cumulatively >15,000 patient-years) for either partial5–10 or
intensive insulin therapy11–13 achieved treatment goals (A1C
<7%) among 40% and 80% of the subjects, respectively. Al-
though this finding is hard to separate from the Hawthorne
effect, when trials have ended and frequent insulin dos-
age adjustment strategy was replaced with infrequent con-
servative care predominantly during clinic appointments,
patients’ A1C was unfavorable merely a year after study
termination.13,14
The nature of this paradox likely ensues from patients’
metabolic behavior. Because of variability within each patient
(Fig. 1), insulin requirements significantly fluctuate over time
and thus cannot be met by infrequent dosage adjustments
during clinic visits (typically once every 3–6 months).
Most clinicians agree that insulin dosage should be titrated/
adjusted far more frequently than during routine clinic visits.
However, the clinical parameters as well as the frequency
required to make effective frequent dosage adjustments are
still controversial. Insulin dosage should not be confused with
insulin doses that for some regimens may depend on pre-
prandial glucose reading (sliding scales or correction factors)
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and carbohydrate intake. A common convention is that diet
and exercise habits need to be explored before insulin dosage
could be adjusted. Some believe that dosage should be ad-
justed every 3 days or even daily. Others believe that carbo-
hydrate counting is crucial for the success of the regimen.
However, it has been established that for patients with type 2
diabetes treated with intensive insulin therapy, carbohydrate
counting is not superior to a sliding scale provided that dosage
is frequently adjusted.12
Many of the aforementioned studies also published the in-
structions given to the study team for frequent insulin dosage
titrations. These instructions advised on frequent insulin dos-
age adjustments solely based on glucose readings.5,7–10,12 Yet,
because these instructions encourage considerable amount of
flexibility and clinical judgment, it is unclear how faithfully
they were followed.15,16
We hypothesize that glucose readings are sufficient to
effectively adjust insulin dosage provided that dosage is ad-
justed every 1–4 weeks. To test the hypothesis, we generated
several algorithms and implemented them in software to
recommend insulin dosage adjustments based only on glu-
cose readings. Glucose readings from log sheets of subjects
treated with intensive insulin therapy that was titrated every
1–4 weeks by a trained study team were used as an input to
the software. While the study team could have been exposed
to multiple clinical parameters, the software relied solely on
glucose readings. The software and the study team’s recom-
mendations for insulin dosage adjustments were systemati-
cally compared using a similarity metric.
Subjects and Methods
Original study design
The original study was designed as a two-center, pro-
spective, randomized, controlled, clinical trial. Inclusion and
exclusion criteria are available elsewhere.11 In brief, subjects
were 60 years of age, had a clinical diagnosis of type 2 di-
abetes for at least 1 year, were taking at least one injection of
insulin per day (with or without oral antidiabetes medica-
tions), and had an A1C 7.0%. One hundred seven subjects
were randomized, and 98 completed follow-up. Patients were
randomized to either multiple daily insulin injections or
continue subcutaneous insulin injections. Of the 54 patients
randomized to multiple daily insulin injections, data from 28
subjects who were followed at the Michigan site were avail-
able for re-analysis. Data from two of the 28 patients were
incomplete and insufficient for re-analysis. The remaining 26
subjects were cumulatively followed for 22 patient-years.
The multiple daily insulin injection regimen consisted of
once-daily insulin glargine (Lantus, Aventis, Bridgewater,
NJ) and preprandial insulin lispro (Humalog, Eli Lilly, In-
dianapolis, IN). All subjects were instructed to monitor their
blood glucose levels before meals and at bedtime. At least
once a week, subjects were instructed to monitor nocturnal
blood glucose levels. Initial basal insulin dosage was calcu-
lated as 50% of the total daily insulin dose and administered
as glargine before bedtime. The remaining 50% was admin-
istered as preprandial lispro boluses and formulated as a
sliding scale. Accordingly, dosagewas given as a combination
of four elements: (1) basal insulin dose, (2) sliding scale for
breakfast, (3) sliding scale for lunch, and (4) sliding scale for
dinner. Dosage adjustments were made once every 1–4 weeks
by the study team, which included three endocrinologists and
two nurses with extensive experience in intensive insulin
therapy. Subjects submitted log sheets (for an example see
Supplementary Appendix; Supplementary Data are available
online at www.liebertonline.com/dia) including dosage giv-
en by the study team, time-tagged glucose reading, and in-
sulin doses. The study team provided a new recommended
dosage on each log sheet, which was later communicated to
the subject via the study coordinator.
Efficacy was assessed by A1C measured at the baseline
and at the 1-, 2-, 4,- 6-, 8-, 10-, and 12-month visits. Safety
was evaluated by the rate of severe hypoglycemia, defined as
capillary glucose 2.8mmol/L (50mg/dL) associated with
neuroglycopenic symptoms that require assistance by another
person. Twenty-three of the 26 subjects successfully and safely
reached A1C<7% (more than 88%), andmean A1C improved
from 7.8% to 6.3%.
Determination of adherence
Subjects’ adherence served as a marker for quality control
to corroborate the weight of the study team’s instructions. For
each patient, lispro meal doses over a period of two randomly
chosen weeks were individually compared to the sliding scale
of the fast-acting insulin boluses. The deviation of each ad-
ministered dose from the expected dose due to the sliding
scale was expressed as a percentage.
Software design
To prove or refute our hypothesis it was mandatory to
refrain from human interference while regenerating dosage
recommendations and comparing them to the study team’s
recommendations. Therefore, we created software with al-
gorithms that processed time-tagged glucose readings and
adjusted insulin dosage while ignoring any additional clinical
parameters. The software was developed by E.B. and I.H.
prior to acquiring the clinical data. W.H.H. and his study
team, from whom the data were acquired,11 were not in-
FIG. 1. Weekly mean glucose levels between clinic visits of
a type 2 diabetes patient with uncontrolled diabetes. This
patient did not take part in the discussed study. Significant
fluctuations in mean glucose levels between visits make
dosage adjustment only during clinical visits inadequate.
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volved in the development of the software. The algorithms
embedded in the software were based on state-of-the-art
guidelines for insulin management17 and on the following
four principles:
1. Time-tagged glucose readings were the only input used
to adjust the current dosage and create recommenda-
tions for the next insulin dosage.
2. Insulin dosage was increased for glucose level above
target and decreased for glucose level below target.
3. The intensity of adjustments decreases as glucose read-
ings get closer to target to prevent unstable oscillations
of dosage.
4. The ability to detect ‘‘outliers.’’ The software utilizes
higher-order statistics to detect outliers and treats them
separately from the remainder of the data.
Similarity between the software
and study team’s recommendations
The database consisted of 630 log sheets (2,520 insulin
dosage adjustments) containing time-tagged glucose read-
ings, previous dosage prescribed by the study team, and a
new set of adjusted dosage (see Supplementary Appendix).
Each log sheet’s glucose readings were processed by the
software. The software generated new recommended dosage
for long-acting insulin and three mealtime fast-acting insu-
lin sliding scales. Because of inherent dependencies, only the
4.4–6.7mmol/L (80–120mg/dL) glucose range of each slid-
ing scale, i.e., each meal bolus dose, was used for comparison.
These four components generated by the software per log
sheet were compared to the original study team’s recom-
mendations using a similarity metric.
Similarity metric
Differences between the study team recommendations and
the software recommendations were classified into six cate-
gories:
1. Identical: the software and study team made the same
dosage recommendation.
2. Within 10%: the dosage recommended by the software
waswithin 10% of the dosage recommended by the study
team. In addition, the two dosage modifications were in
the same direction (i.e., the software did not recommend
increasing the dosage, whereas the study team re-
commended decreasing the dosage, or vice versa).
3. Within 10–20%: the dosage recommended by the soft-
ware was within 10–20% of the dosage recommended
by the study team. In addition, the two dosage modi-
fications were in the same direction.
4. Different; 10–20%: The software recommended increas-
ing the dosage by 10–20%, whereas the study team re-
commended decreasing the dosage.
5. Different; more than 20%: The software recommended
increasing the dosage by more than 20%, while the
study team recommended decreasing the dosage.
6. Other: all other cases (not complying with categories
1–5).
Of the above, categories 4 and 5were defined as ‘‘Different’’
and represented potentially hazardous disagreement between
the software and the study team.
We considered the software recommendations to be ‘‘clin-
ically equivalent’’ to the study team’s recommendations if
they were classified in categories 1, 2, or 3. We assumed that a
20%difference is a reasonable value that can be seen in routine
Table 1. Subjects’ Characteristics Compared to the Original Randomized Study Population
Characteristic
Multiple daily insulin
subjects for re-analysis
Original randomized
population
Subjects (n) 26 107
Age (years) 67.4 4.9 66.2 5.4
Sex (male) 13 (50) 62 (58)
Race
Caucasian 26 (100) 92 (86)
Black 0 6 (5.6)
Hispanic 0 6 (5.6)
Other 0 3 (2.8)
Duration of diabetes (years) 18.3 9.9 15.9 9.0
History of diabetes complications
Retinopathy 9 (34.6) 39 (36)
Nephropathy 5 (19) 16 (15)
Neuropathy 14 (53.8) 69 (64)
History of cardiovascular complications
Hypertension 19 (73) 79 (74)
Dyslipidemia 19 (73) 72 (67)
Cigarette smoking (current) 1 (4) 5 (5)
Ischemic heart disease/heart failure 10 (38) 38 (35)
BMI (kg/m2) 29.9 6.1 32.2 5.7
A1C (%) 7.8 0.7 8.2 1.0
Data are mean SD values or n (%).
No statistically significant differences were noted.
A1C, hemoglobin A1c; BMI, body mass index.
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clinical settings. Moreover, it has been demonstrated that
identical insulin injections can result in different plasma insulin
profiles (can exceed 20%) because of the complex process of in-
sulin absorption anddispersion.18 For illustration,we believe that
it is not unreasonable in clinical settings tohaveone care-provider
increasing lunchtime lispro from 20 units to 21 units and another
from 20 units to 24 units, using data from the same patient. The
difference between these two examples is almost 20%.
Statistical analysis
Subjects’ characteristics were compared to the original
study population by two-tailed Student’s t test for parametric
variables and w2 test for nonparametric variables. Results are
presented as mean SD values. A P value <0.05 was defined
as statistically significant.
The process of insulin dosage recommendations, by either
the study team or the software, is not a random process.
Therefore, we neither performed nor presented statistical
comparisons between the software and study team’s recom-
mendations. Instead, the similarity metric was used to mea-
sure the distance between the two sets.
Results
The re-analyzed subjects represent
the original study population
Data from the 26 subjects treated with multiple daily
insulin injections were available for post hoc analysis.
Table 1 compares the basic characteristics of this cohort
to the original study population that was eligible for
FIG. 2. Similarity between the software and study team’s dosage modifications. (A) Overall similarity between the software
and the study team’s dosage recommendations. (B) Similarity between dosage recommendations analyzed independently for
long-acting insulin (glargine) and fast-acting insulin (lispro). (C) Example of two subjects. The subjects’ hemoglobin A1c
(HgbA1c) levels dropped below 7% in less than 10 weeks, yet dosage kept changing to keep HgbA1c within the desired
range. Discrete points in the upper plot represent the software dosage recommendations compared to the study team’s
recommendations depicted in the curves. (D) Distance between recommendations made by the software and the study team
for subjects with different insulin sensitivity (total daily insulin [in units]/weight [in kg]). The population was analyzed for
subjects who had high (0.3–0.6), medium (0.6–1), or low (1–1.9) insulin sensitivity. The clinical similarity between dosage
modifications made by the software and the study team was not affected by insulin sensitivity.
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randomization (n¼ 107). No significant differences were
identified.
Mean SD A1C of the re-analyzed subjects was 7.8 0.7%
before enrollment (median, 7.7%), and following 12 months
of intensive insulin therapy it was 6.3 0.8% (median,
6.1%) (P< 0.0001). Themean improvement (SD) of A1Cwas
1.5 0.9% (median, 1.6%) and was similar to that of the
original study population. Mean total daily insulin dosage of
the re-analyzed subjects was 66.2 units (0.7 units/kg) at the
beginning of the study and 104.5 units (1.0 units/kg) at the
study’s end. Among the re-analyzed subjects 88.5% (23 of 26)
achieved A1C <7% at the expense of six episodes of severe
hypoglycemia (0.27 events per person-year). Ninety-six per-
cent of the re-analyzed patients had at least one episode of
FIG. 2. (Continued).
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minor hypoglycemia. The frequency of these events was not
statistically different from that observed in the original
study population (in the original study 90% of patients in-
curred minor hypoglycemia, and the frequency of severe
hypoglycemia was 0.16 events per person-year) and was
comparable to that reported in subjects treated with in-
tensive insulin therapy (most available data derive from
patients with type 1 diabetes19–21). Body mass index of
the 26 subjects did not significantly change during the
study (initial value, 29.9 6.1 kg/m2; final value, 30.9
6.5 kg/m2).
Subjects were adherent to the study
team’s instructions
To determine dosing accuracy, 1,239 meal boluses were
compared to the corresponding sliding scales. Each devia-
tion from a prescribed dose was expressed as a percentage.
For instance, if for a pre-lunch glucose level of 10mmol/L
(180mg/dL) a subject was instructed to administer 24 units
of lispro and instead injected 26, this dose was registered as
108.3%. In 77.2% of the instances the reported dose was
identical to the prescribed one. In 13.4% of the instances the
reported dose deviated from the prescribed dosage by
more than 10% (data not shown). We assumed that in these
cases, subjects deviated from the prescribed dose because of
factors such as decreased food intake or increased physical
activity.
Although incorporating only glucose readings,
the software recommendations lie in close proximity
to those recommended by the study team
A database of n¼ 2,520 recommendations was available
for comparison. As shown in Figure 2A, the software
made ‘‘Identical’’ (similarity metric category 1) dosage rec-
ommendations (long-acting and fast-acting insulin) in 42.3%
(n¼ 1,067) of the cases, 38% (n¼ 959) were ‘‘Within 10%’’
(category 2), and 15.2% (n¼ 383) were ‘‘Within 10–20%’’
(category 3).
When analyzed separately, both long-acting (glargine) and
fast-acting (lispro) gave identical or similar recommendations
in 95–97% of the cases, respectively (Fig. 2B). Eight cases
(0.3%) were considered ‘‘Different; 10–20%’’ (category 4). Of
these eight, seven cases were recorded in a single subject
treated with 51 units of insulin/day. These seven cases re-
presented 7.95% of the 88 dosage recommendations for this
particular subject. In all of these cases, the study team re-
commended decreasing the dosage by a single unit, whereas
the software recommended increasing the dosage by a single
unit. The eighth case was recorded in a patient treated with 55
units of insulin/day. In this particular event, the study team
recommended decreasing the patient’s lunch lispro dosage
from 11 to 10 insulin units, whereas the software rec-
ommended increasing the same dosage from 11 to 13 insulin
units. Pre-dinner glucose measurements for the discussed
week were 8, 10, 20.3, 4.4, and 18.7mmol/L (144, 180, 365, 79,
and 337mg/dL). Thus, it is not clear whether the software
recommendation was erroneous. No cases of ‘‘Different;
>20%’’ (category 5) were noted.
Of the 103 cases categorized as ‘‘Other’’ (category 6), in 40
non-clustered episodes (1.6% of the entire data set), the study
team recommended increasing a dosage, whereas the soft-
ware recommended decreasing it. The rest of the ‘‘Other’’
cases included adjustments differing by more than 20%
mostly because of quantization (e.g., if a bolus dosage com-
ponent of 4 units was increased by the study team to 5 units,
whereas it was kept unchanged by the software, the difference
was 25%).
In summary, 95.6% of the software recommendations (us-
ing only glucose measurements to adjust the prior dosage)
yielded clinically equivalent insulin dosage adjustments
when compared with those of the study team.
As illustrated by the examples in Figure 2C, in all subjects,
insulin dosage adjustments were essential not only for in-
duction of intensive insulin therapy but also for maintaining
optimal A1C during the entire study.
Glucose reading is the only parameter required
to frequently adjust insulin dosage,
invariant to insulin sensitivity
To determine whether the similarity between recommen-
dations of the software and the study team was not related to
subjects who required either high or low insulin dosage, we
divided the 2,520 data points into three groups (820, 776, and
924, corresponding to eight, nine, and nine subjects) according
to the subjects’ insulin sensitivity. Insulin sensitivity was
calculated by total daily insulin dose (in units) divided by
weight (in kg) at the end of the trial. The subjects were divided
into the following groups: (A) 0.3–0.6 (21–59 units/day), (B)
0.6–1.0 (52–120 units/day), and (C) 1.0–1.9 (113–232 units/
day).
In all three groups, more than 93% of the software dosage
recommendations were clinically equivalent to the study
team’s dosage recommendations, i.e., no more than 20%
apart (Fig. 2D). Similarity between dosage recommendations
tended to be lower for patients treated with fewer insulin
units per day. This was ascribed to clinically minor differ-
ences of 1–2 units between the software and the study team’s
recommendations. In conclusion, these results suggest that
frequent insulin dosage adjustments can be made based
only on glucose readings independent of patients’ insulin
sensitivity.
Other clinical guidelines for insulin dosage adjustments
based on glucose readings may reasonably correlate
with ones made by trained care-providers
Our software was designed to imitate the decision making
process of a care-provider when adjusting insulin dosage
every 1–4 weeks. Yet, different care-providers may have
different approaches. Although not initially designed to
operate independent of the care-provider input, we im-
plemented in software the guidelines for frequent insulin
dosage adjustments published by Bergenstal et al.12 The
same data used before from the 630 log sheets (2,520 insulin
dosage adjustments) were fed to ‘‘Bergenstal’s guidelines,’’
and the recommendations were compared to the original
recommendations of the study team. In 15.8% of the cases the
guidelines gave identical recommendations to the onesmade
by the study team; in 32.5%, ‘‘within 10%’’; in 39.2%, ‘‘within
10–20%’’; no ‘‘different 10–20%’’ or ‘‘different >20%’’ were
noted; and 12.5% were categorized as ‘‘other’’ (data not
shown).
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Discussion
This report explores the vital clinical parameter required
to facilitate frequent insulin dosage adjustments. Unfortu-
nately, the growing mismatch between patients’ needs and
caregivers’ availability disallows frequent outpatient insulin
dosage adjustments, thus making insulin therapy less effec-
tive. In the preceding analysis, we compared modifications of
insulin dosage (long-acting and mealtime fast-acting) made
by a dedicated software to ones made by an experienced
study team. The only input the software used to adjust insulin
dosage was glucose readings, whereas the study team com-
municated with the patients and could have been exposed to
other clinical parameters. We showed that the software rec-
ommendations were clinically equivalent to the ones made
by the study team. Concomitantly, the original recommen-
dations of the study team were demonstrated to be safe and
effective. Although frequently adjusted insulin therapy has
been supported by multiple studies,5–8,11–13 the optimal fre-
quency of adjustments is yet to be determined. In this study,
subjects were contacted every 1–4 weeks for dosage adjust-
ments and confer superior control without excess of hypo-
glycemia.
The frequency of severe hypoglycemia both in the re-
analyzed cohort and in the original study population was
low as been routinely demonstrated elsewhere and consid-
ered to be beneficial despite its risk.13,14,19–21 In more than
80% of the cases, dosage adjustment recommendations
made by the softwarewere, atmost, within 10%of thosemade
by experienced endocrinologists and nurses. In 15% of the
cases dosage modifications made by the software were within
10–20% of the study team’s recommendations. Similar cor-
relation was demonstrated separately for long-acting and
fast-acting insulin and among subjects with different insulin
sensitivity.
In our metric, the ability of the software to make safe in-
sulin dosage adjustments was assessed by six distance cate-
gories (see Similarity metric). Categories 4 and 5 included
cases in which the software recommended an increase in
dosage whereas the study team recommended decreasing it.
These categories were considered as potentially hazardous
because an overdose of insulin may result in hypoglyce-
mia. Yet, in the eight cases (0.3%) classified as ‘‘Different;
10–20%’’ (category 4) it was unclear whether following the
software recommendations was unreasonable. As outlined in
Figure 2A, no events of ‘‘Different; >20%’’ (category 5) were
identified.
Category 6, i.e., ‘‘Other,’’ was found in 4.1% of the cases.
This category included cases where the study team rec-
ommended increasing a dosage component whereas the
software recommended decreasing the same component. In
these cases it could be inferred that underdosing may lead to
subsequent hyperglycemia, followed by overdosing and fi-
nally hypoglycemia. Our static comparison could not have
unequivocally excluded it. Yet, such episodes occurred rarely
(40 non-clustered cases, or 1.6% of all episodes of dosage
adjustments) and were therefore unlikely to have lead to
hazardous situations if the software were to independently
make frequent dosage adjustments.
Although the software is not intended to operate inde-
pendent of a care-provider’s input, we computed clinical
guidelines for insulin dosage adjustments suggested by a
different institution. We found reasonable correlation imply-
ing that clinical guidelines for frequently adjusted insulin
therapy based on glucose readings do not require additional
parameters to make the therapy effective.
Our study is limited by the fact that subjects were closely
followed and more titrated by an expert study team. Un-
fortunately, in reality, patients are infrequently seen in the
clinic, and their insulin dosage is infrequently adjusted. Still,
only clinical studies that incorporate close follow-up allow the
type of analysis presented. Although the A1C goal set in our
studywas questioned by theACCORD study,22 the ACCORD
patients were treated with multiple diabetes medications and
not only with insulin. Recent analysis of the ACCORD data
did not find insulin therapy to be an independent risk factor
for adverse outcome.23
The software discussed here emulates the decision-making
process of an expert care-provider, coaching the patient to
frequently adjust insulin dosage. Although we fully ac-
knowledge the impact of diet and exercise on diabetes man-
agement, the presented data suggest that glucose readings
alone are sufficient to enable effective and safe insulin dos-
age optimization provided that dosage adjustments are made
frequently. A prospective clinical study where a healthcare
provider uses only glucose data to adjust subjects’ insulin
therapy dosage is planned.
In today’s reality, the overwhelming workload in clinics
and the deficiency in care-providers trained in insulin titration
make frequent insulin dosage adjustments unrealistic. Con-
sequently, only 35% of insulin-treated patients achieve A1C
<7% because insulin dosage is seldom adjusted and regimens
become too rigid to compensate for the dynamic needs of
patients. Dependent on further clinical data, we postulate that
such software has the capacity to enable patients to safely
realize the full benefits of their insulin therapy by adjusting
insulin dosage between appointments in order to achieve
optimal glycemic control. This can alleviate the care-providers
from their impossible task to frequently optimize insulin
therapy, shorten clinic waiting time, and assign more time for
patients’ education and management of co-morbidities.
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